Craniofacial Research Laboratory, Plastic Surgery Section, University of Michigan, Ann Arbor, MI, USA.
Bone. 2013 Aug;55(2):384-90. doi: 10.1016/j.bone.2013.04.005. Epub 2013 Apr 15.
A limitation of mandibular distraction osteogenesis (DO) is the length of time required for consolidation. This drawback subjects patients to possible pin-site infections, as well as a prolonged return to activities of normal daily living. Developing innovative techniques to abridge consolidation periods could be immensely effective in preventing these problematic morbidities. Deferoxamine (DFO) is an angiogenic activator that triggers the HIF-1α pathway through localized iron depletion. We previously established the effectiveness of DFO in enhancing regenerate vascularity at a full consolidation period (28 days) in a murine mandibular DO model. To investigate whether this augmentation in vascularity would function to accelerate consolidation, we progressively shortened consolidation periods prior to μCT imaging and biomechanical testing (BMT).
Three time points (14d, 21d and 28d) were selected and six groups of Sprague-Dawley rats (n = 60) were equally divided into control (C) and experimental (E) groups for each time period. Each group underwent external fixator placement, mandibular osteotomy, and a 5.1 mm distraction. During distraction, the experimental groups were treated with DFO injections into the regenerate gap. After consolidation, mandibles were imaged and tension tested to failure. ANOVA was conducted between groups, and p < 0.05 was considered statistically significant.
At 14 days of consolidation the experimental group demonstrated significant increases in bone volume fraction (BVF), bone mineral density (BMD) and ultimate load (UL) in comparison to non-treated controls. The benefit of treatment was further substantiated by a striking 100% increase in the number of bony unions at this early time-period (C:4/10 vs. E:8/10). Furthermore, metrics of BVF, BMD, Yield and UL at 14 days with treatment demonstrated comparable metrics to those of the fully consolidated 28d control group.
Based on these findings, we contend that augmentation of vascular density through localized DFO injection delivers an efficient means for accelerating bone regeneration without significantly impacting bone quality or strength.
下颌骨牵引成骨术(DO)的一个局限性是需要较长的时间来进行骨整合。这一缺点使患者有可能发生针道感染,并延长恢复正常日常生活活动的时间。开发创新技术来缩短整合期可能会非常有效地预防这些有问题的发病率。去铁胺(DFO)是一种血管生成激活剂,通过局部铁耗竭触发 HIF-1α 途径。我们之前已经证实,DFO 在增强我们的鼠下颌骨 DO 模型中完全整合期(28 天)的再生血管生成方面是有效的。为了研究这种血管生成的增强是否能加速整合,我们在 μCT 成像和生物力学测试(BMT)之前逐步缩短整合期。
选择了三个时间点(14d、21d 和 28d),并将 60 只 Sprague-Dawley 大鼠(n = 60)平均分为对照组(C)和实验组(E),每个时间点各有 6 组。每组均行外固定器放置、下颌骨切开和 5.1mm 牵引。在牵引过程中,实验组将 DFO 注入再生间隙。整合后,对下颌骨进行成像和拉伸至失效。对组间进行方差分析,p < 0.05 被认为具有统计学意义。
在整合的 14 天内,实验组的骨体积分数(BVF)、骨矿物质密度(BMD)和极限载荷(UL)与未经治疗的对照组相比有显著增加。在这个早期阶段,治疗组的骨融合数量增加了 100%(C:4/10 vs. E:8/10),这进一步证实了治疗的益处。此外,治疗组在 14 天时的 BVF、BMD、屈服和 UL 等指标与完全整合的 28 天对照组的指标相当。
基于这些发现,我们认为通过局部 DFO 注射增加血管密度是一种加速骨再生的有效方法,而不会显著影响骨质量或强度。